Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Thoracic 3Genitourinary 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Gastrointestinal 2CNS 2Breast 2Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 25Myelodysplastic Syndromes 17Lymphoma, Non-Hodgkin 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Large B-Cell, Diffuse 14Lymphoma, T-Cell, Peripheral 13Multiple Myeloma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Recurrence 10Leukemia 10Hodgkin Disease 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell 7Lymphoma, Follicular 7Hematologic Neoplasms 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Biphenotypic, Acute 6Lymphoma, Extranodal NK-T-Cell 5Leukemia, Myelomonocytic, Chronic 5Primary Myelofibrosis 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, B-Cell 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Immunoblastic Lymphadenopathy 4Prostatic Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3

Interventions

pembrolizumab 6Paclitaxel 4Cyclophosphamide 4Psychiatric Rehabilitation 3Flow Cytometry 3Filgrastim 3Drug Therapy 3Carboplatin 3valspodar 2trametinib 2sargramostim 2epacadostat 2dabrafenib 2X-Rays 2Specimen Handling 2Nivolumab 2Microarray Analysis 2Methylprednisolone 2Melphalan 2Injections 2Immunologic Techniques 2Gemcitabine 2Dexamethasone 2Dasatinib 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Azacitidine × Lymphoid × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡